Literature DB >> 17210938

Costs of cancer care: a view from the centers for Medicare and Medicaid services.

Peter B Bach1.   

Abstract

Fee-for-service Medicare pays for a very substantial portion of all cancer care delivered in the United States. By virtue of its size and visibility, its payment policies at times also influence those of other health care payers. As a result, Medicare affects both the overall economics and the incentive structures of oncology care. Three aspects of how Medicare finances cancer care are particularly germane to the issue of costs. First, Medicare finances all aspects of cancer care in independent payment units, paying separately for physician services, laboratory tests, procedures, imaging, radiation, drug administration, and drugs. Second, Medicare is currently managing and monitoring a very substantial overhaul in payment for cancer care, which aims to reduce or eliminate incentives that have favored aggressive and costly treatments in clinical situations where alternative therapeutic approaches might have been equivalent or preferable. Third, Medicare is trying to increase the focus on care quality and transparency, as improved efficiency and greater value is needed if costs of care are to be contained. Understanding these three aspects of cancer care financing can help clarify what Medicare is capable of doing to control the rising costs that are occurring in cancer today.

Entities:  

Mesh:

Year:  2007        PMID: 17210938     DOI: 10.1200/JCO.2006.08.6116

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  15 in total

1.  Strategies for recruiting Middle Eastern-American young adults for physical activity research: a case of snowballs and Salaam.

Authors:  David Kahan; Alia Al-Tamimi
Journal:  J Immigr Minor Health       Date:  2008-01-23

2.  Talking With Patients About the Cost of Cancer Care.

Authors:  Back Anthony
Journal:  J Oncol Pract       Date:  2007-05       Impact factor: 3.840

3.  Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.

Authors:  Angela Mariotto; Jinani Jayasekerea; Valentina Petkov; Clyde B Schechter; Lindsey Enewold; Kathy J Helzlsouer; Eric J Feuer; Jeanne S Mandelblatt
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

4.  A model to estimate human resource needs for the treatment of outpatients with cancer.

Authors:  Gianpiero Fasola; Giuseppe Aprile; Marianna Aita
Journal:  J Oncol Pract       Date:  2011-11-29       Impact factor: 3.840

Review 5.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

6.  Private Practice Administrative Costs Influenced by Insurance Payer Mix.

Authors:  Jorge M Luna; Paul W Thurman; Margaret Wolfe; Daniel Yagoda; Edward Reed; William D Figg
Journal:  J Oncol Pract       Date:  2009-11       Impact factor: 3.840

7.  Out-of-pocket expenses and treatment choice for men with prostate cancer.

Authors:  Olivia S Jung; Thomas Guzzo; David Lee; Michael Mehler; John Christodouleas; Curtiland Deville; Genevieve Hollis; Anand Shah; Neha Vapiwala; Alan Wein; Mark Pauly; Justin E Bekelman
Journal:  Urology       Date:  2012-10-23       Impact factor: 2.649

8.  Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes.

Authors:  Kevin T Stroupe; Elizabeth Tarlov; Thomas W Weichle; Qiuying L Zhang; Laura C Michaelis; Howard Ozer; Ramon Durazo-Arvizu; Denise M Hynes
Journal:  Support Care Cancer       Date:  2014-06-10       Impact factor: 3.603

9.  Medical oncologists' perceptions of financial incentives in cancer care.

Authors:  Jennifer L Malin; Jane C Weeks; Arnold L Potosky; Mark C Hornbrook; Nancy L Keating
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

10.  The cost of breast cancer screening in the Medicare population.

Authors:  Cary P Gross; Jessica B Long; Joseph S Ross; Maysa M Abu-Khalaf; Rong Wang; Brigid K Killelea; Heather T Gold; Anees B Chagpar; Xiaomei Ma
Journal:  JAMA Intern Med       Date:  2013-02-11       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.